Skip to main content

Table 3 Logistic regression model identifying factors for distant recurrence agreement between TACT and routine datasets

From: Can routine data be used to support cancer clinical trials? A historical baseline on which to build: retrospective linkage of data from the TACT (CRUK 01/001) breast cancer trial and the National Cancer Data Repository

  Odds ratio 95% CI P value
Year relapse reported 0.88 0.80, 0.97 0.01
Distant relapse site = lung 0.61 0.38, 0.98 0.04
Distant relapse site = brain 2.96 1.29, 6.77 0.01
Centre [A] 0.28 0.07, 1.09 0.07
Centre [B] 0.41 0.06, 2.98 0.38
Centre [C] 1.31 0.19, 8.83 0.78
Centre [D] 0.18 0.03, 0.99 0.05
Centre [E] 0.29 0.05, 1.58 0.15
Centre [F] 0.30 0.06, 1.45 0.14
Centre [G] 0.34 0.06, 1.83 0.21
Centre [H] 0.04 0.01, 0.23 < 0.001
Centre [I] 0.05 0.01, 0.29 0.001
Centre [J] 0.07 0.02, 0.33 0.001
Centre [K] 0.28 0.05, 1.52 0.14
Centre [L] 0.31 0.05, 1.92 0.21
Centre [M] 0.37 0.06, 2.29 0.29
Centre [N] 0.37 0.09, 1.61 0.19
Centre [O] 0.07 0.01, 0.43 0.004
Centre [P] 0.23 0.05, 1.19 0.08
Centre [Q] 0.66 0.09, 4.60 0.68
Centre [R] 0.06 0.01, 0.37 0.002
Centre [S] 0.14 0.03, 0.58 0.007
Centre [T] 0.19 0.04, 0.84 0.03
Centre [U] 0.11 0.02, 0.60 0.01
Centre [V] 0.08 0.02, 0.39 0.002
Centre [W] 0.15 0.04, 0.60 0.007
Centre [X] 0.07 0.01, 0.38 0.002
Centre [Y] 0.10 0.02, 0.50 0.005
  1. OR < 1 imply distant recurrence less likely to be identified in NCDR dataset compared to gold standard TACT dataset. Individual centres included in the model have been anonymised. TACT Taxotere and Adjuvant ChemoTherapy